Naris Nilubol1, Roxanne Merkel1, Lily Yang1, Dhaval Patel1, James C Reynolds2, Samira M Sadowski3, Vladimir Neychev4, Electron Kebebew1. 1. Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 2. Nuclear Medicine Department, Clinical Research Center, National Institutes of Health, Bethesda, MD, USA. 3. Thoracic and Endocrine Surgery, University Hospitals of Geneva, Geneva, Switzerland. 4. Department of Surgery, University Multiprofile Hospital for Active Treatment 'Alexandrovska', Medical University, Sofia, Bulgaria.
Abstract
OBJECTIVE: Valproic acid (VA) is a histone deacetylase (HDAC) inhibitor that has antiproliferative effects on several types of cancer, including thyroid cancer. In addition, VA has been reported to upregulate the sodium-iodine symporter in thyroid cancer cells and increases radioiodine uptake in preclinical studies. The aim of this study was to assess the antiproliferative effects of VA and to evaluate if VA can increase the radioiodine uptake in patients with advanced, radioiodine-negative thyroid cancer. DESIGN: An open-label Simon two-stage phase II trial. PATIENTS AND MEASUREMENTS: Valproic acid was administered orally, and doses were adjusted to maintain serum trough levels between 50 and 100 mg/l for 10 weeks, followed by injections of recombinant human thyroid-stimulating hormone and a radioiodine uptake scan. Anatomical imaging studies were performed at week 16 to assess tumour response and radioiodine therapy in patients with increased radioiodine uptake. RESULTS: Thirteen patients with a median age of 66 years (50-78 years) were enrolled and evaluated. Seven patients had papillary thyroid cancer (PTC), two had follicular variant PTC, two had follicular thyroid cancer, and two had Hürthle cell carcinoma. None of the 10 patients who completed the 10-week treatment had increased radioiodine uptake at their tumour sites. Three patients were taken off the study prior to the 10-week radioiodine uptake scan: one with grade-3 hepatic toxicity, one with disease progression and one for noncompliance. Four of 13 patients had decreased stimulated serum thyroglobulin with VA treatment. None of the patients had complete or partial responses based on Response Evaluation Criteria in Solid Tumors (RECIST), and six patients had disease progression. CONCLUSIONS: Valproic acid does not increase radioiodine uptake and does not have anticancer activity in patients with advanced, radioiodine-negative thyroid cancer of follicular cell origin.
OBJECTIVE:Valproic acid (VA) is a histone deacetylase (HDAC) inhibitor that has antiproliferative effects on several types of cancer, including thyroid cancer. In addition, VA has been reported to upregulate the sodium-iodine symporter in thyroid cancer cells and increases radioiodine uptake in preclinical studies. The aim of this study was to assess the antiproliferative effects of VA and to evaluate if VA can increase the radioiodine uptake in patients with advanced, radioiodine-negative thyroid cancer. DESIGN: An open-label Simon two-stage phase II trial. PATIENTS AND MEASUREMENTS: Valproic acid was administered orally, and doses were adjusted to maintain serum trough levels between 50 and 100 mg/l for 10 weeks, followed by injections of recombinant human thyroid-stimulating hormone and a radioiodine uptake scan. Anatomical imaging studies were performed at week 16 to assess tumour response and radioiodine therapy in patients with increased radioiodine uptake. RESULTS: Thirteen patients with a median age of 66 years (50-78 years) were enrolled and evaluated. Seven patients had papillary thyroid cancer (PTC), two had follicular variant PTC, two had follicular thyroid cancer, and two had Hürthle cell carcinoma. None of the 10 patients who completed the 10-week treatment had increased radioiodine uptake at their tumour sites. Three patients were taken off the study prior to the 10-week radioiodine uptake scan: one with grade-3 hepatic toxicity, one with disease progression and one for noncompliance. Four of 13 patients had decreased stimulated serum thyroglobulin with VA treatment. None of the patients had complete or partial responses based on Response Evaluation Criteria in Solid Tumors (RECIST), and six patients had disease progression. CONCLUSIONS:Valproic acid does not increase radioiodine uptake and does not have anticancer activity in patients with advanced, radioiodine-negative thyroid cancer of follicular cell origin.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Wen T Shen; Ted S Wong; Woong-Youn Chung; Mariwil G Wong; Electron Kebebew; Quan-Yang Duh; Orlo H Clark Journal: Surgery Date: 2005-12 Impact factor: 3.982
Authors: Rosália P Padovani; Teresa S Kasamatsu; Claudia C D Nakabashi; Cleber P Camacho; Danielle M Andreoni; Eduardo Z Malouf; Marilia M S Marone; Rui M B Maciel; Rosa Paula M Biscolla Journal: Thyroid Date: 2012-07-24 Impact factor: 6.568
Authors: William Kevin Kelly; Owen A O'Connor; Lee M Krug; Judy H Chiao; Mark Heaney; Tracy Curley; Barbara MacGregore-Cortelli; William Tong; J Paul Secrist; Lawrence Schwartz; Stacy Richardson; Elaina Chu; Semra Olgac; Paul A Marks; Howard Scher; Victoria M Richon Journal: J Clin Oncol Date: 2005-05-16 Impact factor: 44.544
Authors: Vahab Fatourechi; Ian D Hay; Houman Javedan; Gregory A Wiseman; Brian P Mullan; Colum A Gorman Journal: J Clin Endocrinol Metab Date: 2002-04 Impact factor: 5.958
Authors: Marie-Claude Hofmann; Muthusamy Kunnimalaiyaan; Jennifer R Wang; Naifa L Busaidy; Steven I Sherman; Stephen Y Lai; Mark Zafereo; Maria E Cabanillas Journal: Endocr Relat Cancer Date: 2022-09-14 Impact factor: 5.900
Authors: Theresa K Leslie; Andrew D James; Fulvio Zaccagna; James T Grist; Surrin Deen; Aneurin Kennerley; Frank Riemer; Joshua D Kaggie; Ferdia A Gallagher; Fiona J Gilbert; William J Brackenbury Journal: Biochim Biophys Acta Rev Cancer Date: 2019-07-23 Impact factor: 10.680
Authors: Ernestina Marianna De Francesco; Marcello Maggiolini; Herbert B Tanowitz; Federica Sotgia; Michael P Lisanti Journal: Oncotarget Date: 2017-06-12
Authors: Shamini Murugavel; Antoinette Bugyei-Twum; Pratiek N Matkar; Husain Al-Mubarak; Hao H Chen; Mohamed Adam; Shubha Jain; Tanya Narang; Rawand M Abdin; Mohammad Qadura; Kim A Connelly; Howard Leong-Poi; Krishna K Singh Journal: Front Pharmacol Date: 2018-07-11 Impact factor: 5.810